← Back to Patent Explorer
US5225419A Expired / Lapsed US ⏱️ 0.0 years remaining

Certain 1,8-ethano or propano-1,4-dihydro-4-oxo-quinoline-3-carboxamides and derivatives thereof

Assignee: John Wyeth and Brother Ltd
•
Filing: 1991-09-16
•
Granted: 1993-07-06
•
Expires: 2011-09-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds of formula ##STR1## wherein R 1 is hydrogen or one or more specified substituents, X is --O--or --NR 2 -- where R 2 is lower alkyl, lower alkenyl, lower alkynyl, aryl or specified substituted lower alkyl or R 2 represents a group --Z-- which is connected to the 8-position of the aromatic ring so as to form a heterocyclic ring of 5 to 7 ring members, Y is O or NR 3 where R 3 is hydrogen or lower alkyl, and B is a saturated azabicyclic ring (eg tropanyl or quinuclidinyl) or a N-oxide thereof and their acid addition salts are 5-HT 3 antagonists which may be used in, for example, the treatment of neuro-psychiatric disorders.

Inventors

  • 👤 Terence J. Ward
  • 👤 Janet C. White

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 03:37
CPC Classifications
C; C07; C07D; C07D451/00; C07D451/02; C07D451/04; C07D451/14

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 146 words
A compound of the formula ##STR13## or a pharmaceutically acceptable acid addition salt thereof, in which R 1 represents hydrogen or one or more substituents selected from lower alkyl, hydroxy, lower alkoxy, halogen, methylenedioxy, halo(lower)alkyl, nitro, amino, (lower)alkylamino and di(lower)alkylamino; X represents a group of formula --Z-- which is connected to the 8-position of the aromatic ring so as to form a heterocyclic ring of 5-6 ring members wherein the ring members represented by Z are two or three methylene groups optionally substituted by one or more lower alkyl groups and the X position of the --Z-- chain is N; Y represents O or NR 3 where R 3 is hydrogen or lower alkyl and B represents a saturated azabicyclic ring, or an N-oxide thereof, wherein the saturated azabicyclic ring has the formula ##STR14## where m is 2 or 3 R 4 is hydrogen or (lower)alkyl.
Claim 2
Dependent Claim 146 words
A compound of the formula ##STR13## or a pharmaceutically acceptable acid addition salt thereof, in which R 1 represents hydrogen or one or more substituents selected from lower alkyl, hydroxy, lower alkoxy, halogen, methylenedioxy, halo(lower)alkyl, nitro, amino, (lower)alkylamino and di(lower)alkylamino; X represents a group of formula --Z-- which is connected to the 8-position of the aromatic ring so as to form a heterocyclic ring of 5-6 ring members wherein the ring members represented by Z are two or three methylene groups optionally substituted by one or more lower alkyl groups and the X position of the --Z-- chain is N; Y represents O or NR 3 where R 3 is hydrogen or lower alkyl and B represents a saturated azabicyclic ring, or an N-oxide thereof, wherein the saturated azabicyclic ring has the formula ##STR14## where m is 2 or 3 R 4 is hydrogen or (lower)alkyl.
Claim 3
Dependent Claim 16 words
A compound as claimed in claim 1 where m is 2 and R 4 is methyl.
Claim 4
Dependent Claim 17 words
A compound as claimed in claim 1 which is (endo)-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl-1,8-ethano-1,4-dihydro-4-oxoquinoline-3-carboxamide or a pharmaceutically acceptable addition salt thereof.
Claim 5
Dependent Claim 17 words
A compound as claimed in claim 1 which is (endo)-N-(8-aza-8-methylbicyclo[3.2.1]octan-3-yl)-1,4-dihydro-1,8-propanoquinolin-4-one-3-carboxamide or a pharmaceutically acceptable addition salt thereof.
Claim 6
Dependent Claim 21 words
A pharmaceutical composition comprising an effective amount of a compound claimed in claim 1 in association with a pharmaceutically acceptable carrier.

References Cited (Backward Citations)

GB2125398A Cited
WO1984003281A1 Cited
GB2145416A Cited
EP0200444A2 Cited
DE3827253A1 Cited
EP0382687A2 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1996-07-05 1997-01-04 1997-07-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2000-07-05 2001-01-04 2001-07-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2004-07-05 2005-01-04 2005-07-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag